礼来(Eli Lilly)股价在盘前交易中下跌4.1%，此前路透社报道称，在线药房Hims & Hers Health计划推出一款仿制诺和诺德(Novo Nordisk)热门减肥药Wegovy的口服片剂，定价为每月49美元。
该报道指出，Hims & Hers推出的这款仿制药主要成分与Wegovy相同，均为司美格鲁肽(semaglutide)，但将以远低于品牌药的价格销售，可能对包括礼来在内的现有减肥药市场参与者构成价格竞争压力。
市场分析认为，如果更多仿制药企业以低价策略进入市场，可能会侵蚀礼来旗下减肥药物Mounjaro和Zepbound的市场份额及定价能力，从而影响其未来收入增长预期，这可能是导致礼来股价今日盘前下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.